Thus, the reason why treatment with IL-2 results in a significant decrease in tumor in mouse models but yields a poor result in some patients with melanoma or renal cell cancer is that IL-2 promotes the proliferation of Treg cells [86,130]. This evidence concerns the gene IL2 and renal cell adenocarcinoma.